AbbVie completed the acquisition of Apogee Therapeutics.
Public source
Publisher name
Public post
Today, AbbVie announced the successful completion of our acquisition of Apogee Therapeutics. This is an important step in strengthening our Immunology leadership, advanc…
Company
AbbVie
- Industry
- Pharmaceutical Manufacturing
- Location
- North Chicago, US
- Company size
- 10,001+ employees
About AbbVie
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
See moreLatest activity
Latest activity from AbbVie
79 signals
Research & Knowledge
AbbVie published a new European Insight Paper in partnership with the European CLL Association (ECLLA) addressing key gaps in chronic lymphocytic leukemia care, informed by clinical evidence and global patient data from the 2026 European Hematology Association (EHA) Congress.
People
AbbVie is hiring a Patient Relations Manager for the UK External Affairs team.
People
AbbVie is hiring a Communications Manager for the UK External Affairs team.
Discover more
Similar signals
Similar public activity from other companies.
Strategy & Corporate Development
Apogee Therapeutics
Apogee Therapeutics is now part of AbbVie
Strategy & Corporate Development
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. completed the acquisition of Alkeus Pharmaceuticals, Inc.
Strategy & Corporate Development
Servier Pharmaceuticals
Servier Pharmaceuticals expanded its rare neurology portfolio through the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business.
Strategy & Corporate Development
Servier
Servier completed the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business to strengthen its commitment to rare neurological disorders and advance innovation for patients with Duchenne and Becker muscular dystrophies.
Strategy & Corporate Development
Sanofi